ERFSF logo

Eurofins Scientific SE (ERFSF)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Eurofins Scientific SE (ERFSF) with AI Score 43/100 (Weak). Eurofins Scientific SE provides analytical testing and laboratory services globally. The company operates in diverse sectors, including agroscience, biopharma, food, environment, and consumer products. Market cap: 0, Sector: Healthcare.

Last analyzed: Mar 18, 2026
Eurofins Scientific SE provides analytical testing and laboratory services globally. The company operates in diverse sectors, including agroscience, biopharma, food, environment, and consumer products.
43/100 AI Score

Eurofins Scientific SE (ERFSF) Healthcare & Pipeline Overview

Employees65,694
HeadquartersLuxembourg, Luxembourg

Eurofins Scientific SE is a global leader in analytical testing and laboratory services, providing a comprehensive suite of solutions across diverse sectors, including food, environment, pharmaceuticals, and consumer products. The company's extensive network and scientific expertise position it as a key player in ensuring safety and quality standards worldwide.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 18, 2026

Investment Thesis

Eurofins Scientific SE presents a compelling investment case due to its diversified service offerings and global presence in the analytical testing market. With a market capitalization of $12.91 billion, the company benefits from a stable revenue stream driven by regulatory requirements and increasing consumer demand for safety and quality. A gross margin of 22.5% and an ROE of 9.5% indicate solid profitability. Ongoing: The company's strategic acquisitions and expansion into high-growth areas such as biopharma and environmental testing are expected to drive future revenue growth. However, a debt-to-equity ratio of 96.84 and a beta of 0.94 suggest moderate financial risk and market sensitivity.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $12.91 billion reflects its significant presence in the analytical testing market.
  • Profit margin of 6.5% indicates moderate profitability within the competitive diagnostics and research sector.
  • Gross margin of 22.5% demonstrates the company's ability to generate revenue above the cost of goods sold.
  • Return on Equity (ROE) of 9.5% suggests efficient utilization of shareholder equity to generate profits.
  • Debt-to-Equity ratio of 96.84 indicates a relatively high level of financial leverage.

Competitors & Peers

Strengths

  • Global presence with an extensive network of laboratories.
  • Diversified service offerings across multiple industries.
  • Strong reputation for scientific expertise and quality.
  • Proven track record of strategic acquisitions and growth.

Weaknesses

  • High debt-to-equity ratio.
  • Exposure to regulatory changes and compliance risks.
  • Dependence on acquisitions for growth.
  • Potential for price competition in certain markets.

Catalysts

  • Upcoming: Expansion of biopharma testing services to capitalize on the growing biopharmaceutical industry.
  • Ongoing: Strategic acquisitions to expand service offerings and geographic reach.
  • Ongoing: Increasing focus on environmental testing to meet growing demand for environmental monitoring.
  • Ongoing: Leveraging technological advancements to improve efficiency and accuracy of testing processes.

Risks

  • Potential: High debt-to-equity ratio could limit financial flexibility.
  • Potential: Changes in regulatory requirements and compliance standards could increase costs.
  • Potential: Economic downturns could reduce spending on testing services.
  • Ongoing: Intense competition from other testing laboratories could put pressure on pricing.
  • Potential: Product liability claims and recalls could damage reputation and financial performance.

Growth Opportunities

  • Expansion in Biopharma Testing: The biopharmaceutical industry is experiencing rapid growth, driven by the development of novel therapies and increasing regulatory scrutiny. Eurofins can capitalize on this trend by expanding its biopharma testing services, including drug discovery, clinical trials, and quality control. The global biopharmaceutical testing market is projected to reach $120 billion by 2027, offering significant growth potential for Eurofins. Timeline: Ongoing.
  • Increasing Focus on Environmental Testing: Growing concerns about environmental pollution and climate change are driving demand for environmental testing services. Eurofins can leverage its expertise in water, air, and soil testing to capture a larger share of this market. The global environmental testing market is expected to reach $35 billion by 2026, presenting a substantial opportunity for Eurofins. Timeline: Ongoing.
  • Growth in Food Safety Testing: With increasing consumer awareness of food safety and stricter regulations, the demand for food testing services is growing. Eurofins can expand its food testing capabilities, including allergen testing, GMO testing, and pesticide residue testing, to meet this demand. The global food safety testing market is projected to reach $22 billion by 2025, providing a significant growth avenue for Eurofins. Timeline: Ongoing.
  • Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid economic growth and increasing demand for testing and analytical services. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. The growth in these regions offers substantial opportunities for Eurofins to increase its global market share. Timeline: Ongoing.
  • Strategic Acquisitions: Eurofins has a history of growth through strategic acquisitions. By acquiring smaller testing laboratories and specialized service providers, Eurofins can expand its service offerings, geographic reach, and customer base. This strategy allows Eurofins to quickly enter new markets and gain access to specialized expertise. Timeline: Ongoing.

Opportunities

  • Expansion in high-growth areas such as biopharma and environmental testing.
  • Penetration of emerging markets with increasing demand for testing services.
  • Leveraging technological advancements to improve efficiency and accuracy.
  • Increasing outsourcing of testing services by large corporations.

Threats

  • Economic downturns and reduced spending on testing services.
  • Increased competition from other testing laboratories.
  • Changes in regulatory requirements and compliance standards.
  • Potential for product liability claims and recalls.

Competitive Advantages

  • Extensive network of laboratories across the globe.
  • Wide range of testing services across various industries.
  • Strong reputation for scientific excellence and customer service.
  • Strategic acquisitions to expand service offerings and geographic reach.

About ERFSF

Founded in 1987 and headquartered in Luxembourg, Eurofins Scientific SE has grown from a small food testing laboratory to a global leader in analytical testing and laboratory services. The company's initial focus on food authenticity testing has expanded significantly to encompass a wide range of industries, including pharmaceuticals, environmental science, agriculture, and consumer products. Eurofins provides services such as agroscience, biopharma, clinical diagnostics, and consumer product testing. Its offerings include biological assessment, consumer and human safety testing, product chemistry, regulatory consultancy, and seed services. The company also provides assurance services, including sustainability audits, certification, quality inspection, and food and dietary supplement labeling. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. It also offers specialized testing services such as forensic, genomic, maritime, materials and engineering, and sensory and consumer services. Eurofins' commitment to scientific excellence and customer service has driven its growth, making it a trusted partner for businesses seeking to ensure the safety, quality, and compliance of their products and processes.

What They Do

  • Provides analytical testing services for food, environment, pharmaceutical, and consumer products.
  • Offers laboratory services, including water, air, and soil testing.
  • Conducts biological assessments and product chemistry testing.
  • Provides regulatory consultancy and seed services.
  • Offers sustainability audits, certification, and quality inspection services.
  • Provides clinical diagnostics and biopharma testing services.
  • Offers forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services.

Business Model

  • Generates revenue by providing analytical testing and laboratory services to various industries.
  • Offers a wide range of testing services, including food, environment, pharmaceutical, and consumer products.
  • Operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste.
  • Acquires smaller testing laboratories and specialized service providers to expand its service offerings and geographic reach.

Industry Context

Eurofins Scientific SE operates in the diagnostics and research industry, which is characterized by increasing demand for testing and analytical services driven by stringent regulatory requirements and growing consumer awareness of safety and quality. The global market for testing, inspection, and certification is projected to reach $250 billion by 2028, growing at a CAGR of 4.5%. Eurofins competes with companies such as SGS SA, Intertek Group, and Bureau Veritas, offering a wide range of testing services across various sectors. The industry is also influenced by technological advancements, such as automation and data analytics, which are improving the efficiency and accuracy of testing processes.

Key Customers

  • Food manufacturers and processors
  • Pharmaceutical companies
  • Environmental agencies and organizations
  • Consumer product manufacturers
  • Government agencies
AI Confidence: 81% Updated: Mar 18, 2026

Financials

Chart & Info

Eurofins Scientific SE (ERFSF) stock price: Price data unavailable

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ERFSF.

Price Targets

Wall Street price target analysis for ERFSF.

MoonshotScore

43/100

What does this score mean?

The MoonshotScore rates ERFSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

ERFSF OTC Market Information

ERFSF trades on the OTC Other market tier of OTC Markets.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown

ERFSF Healthcare Stock FAQ

What does Eurofins Scientific SE do?

Eurofins Scientific SE is a global provider of analytical testing and laboratory services. It offers a comprehensive range of testing services across various industries, including food, environment, pharmaceuticals, and consumer products. The company's services include food safety testing, environmental monitoring, pharmaceutical testing, and consumer product testing. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. The company's mission is to provide its customers with high-quality testing services that ensure the safety, quality, and compliance of their products and processes.

What do analysts say about ERFSF stock?

Analyst consensus on Eurofins Scientific SE (ERFSF) is currently pending, but key valuation metrics and growth considerations are being closely monitored. The company's diversified service offerings and global presence in the analytical testing market are viewed as positive factors. However, its high debt-to-equity ratio and exposure to regulatory changes are potential concerns. Investors are advised to conduct their own due diligence and consider their individual risk tolerance before making any investment decisions. Further AI analysis is pending.

What are the main risks for ERFSF?

Eurofins Scientific SE faces several risks, including a high debt-to-equity ratio, which could limit its financial flexibility. The company is also exposed to regulatory changes and compliance risks, which could increase costs and impact its profitability. Economic downturns could reduce spending on testing services, affecting the company's revenue. Intense competition from other testing laboratories could put pressure on pricing and margins. Additionally, product liability claims and recalls could damage the company's reputation and financial performance. These risks should be carefully considered by investors.

How does Eurofins Scientific SE navigate regulatory approval processes?

Eurofins Scientific SE navigates regulatory approval processes by maintaining a strong focus on compliance and quality. The company employs a team of regulatory experts who stay up-to-date on the latest regulations and guidelines. Eurofins also invests in state-of-the-art equipment and technology to ensure the accuracy and reliability of its testing services. The company works closely with regulatory agencies to ensure that its testing methods and procedures meet the required standards. Eurofins' commitment to compliance and quality has enabled it to obtain and maintain regulatory approvals for its testing services in various industries and regions.

What are the key growth opportunities for ERFSF in healthcare?

Eurofins Scientific SE has several key growth opportunities in the healthcare sector. The company can expand its biopharma testing services to capitalize on the growing biopharmaceutical industry. Eurofins can also increase its focus on clinical diagnostics, providing testing services for diseases and medical conditions. The company can leverage its expertise in genomics to offer personalized medicine testing services. Additionally, Eurofins can expand its presence in emerging markets, where healthcare spending is increasing. These growth opportunities position Eurofins to become a leading provider of testing services in the healthcare sector.

What are the key factors to evaluate for ERFSF?

Eurofins Scientific SE (ERFSF) currently holds an AI score of 43/100, indicating low score. Key strength: Global presence with an extensive network of laboratories.. Primary risk to monitor: Potential: High debt-to-equity ratio could limit financial flexibility.. This is not financial advice.

How frequently does ERFSF data refresh on this page?

ERFSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ERFSF's recent stock price performance?

Recent price movement in Eurofins Scientific SE (ERFSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Global presence with an extensive network of laboratories.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • The information provided in this dossier is based on available data and analysis as of March 18, 2026. Market conditions and company performance may change over time.
  • AI analysis is pending and may provide further insights into the company's performance and prospects.
Data Sources

Popular Stocks